Last updated on February 2020

Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics


Brief description of study

The trial is a randomized, open-label phase III study comparing CPX-351 vs conventional intensive induction and consolidation chemotherapy in patients with newly diagnosed AML and intermediate- or adverse-risk genetics (according to 2017 ELN criteria), including AML with myelodysplasia-related changes (AML-MRC) and therapy-related AML according to the World Health Organization (WHO) classification. Event-free survival (EFS) will be the primary endpoint as defined by standard criteria (Dhner 2017).

Clinical Study Identifier: NCT03897127

Find a site near you

Start Over

Klinikum Aschaffenburg

Aschaffenburg, Germany
  Connect »

Klinikum L denscheid

Lüdenscheid, Germany
  Connect »

Klinikum L denscheid

Lüdenscheid, Germany
  Connect »